Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Net Income (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Net Income for 6 consecutive years, with -$79.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Income rose 3.63% year-over-year to -$79.1 million, compared with a TTM value of -$224.8 million through Sep 2025, up 12.81%, and an annual FY2024 reading of -$220.7 million, down 5.89% over the prior year.
  • Net Income was -$79.1 million for Q3 2025 at Autolus Therapeutics, down from -$47.9 million in the prior quarter.
  • Across five years, Net Income topped out at -$27.0 million in Q4 2022 and bottomed at -$82.1 million in Q3 2024.
  • Average Net Income over 4 years is -$51.5 million, with a median of -$46.9 million recorded in 2023.
  • The sharpest move saw Net Income crashed 140.13% in 2023, then soared 57.39% in 2024.
  • Year by year, Net Income stood at -$27.0 million in 2022, then plummeted by 140.13% to -$64.8 million in 2023, then skyrocketed by 57.39% to -$27.6 million in 2024, then plummeted by 186.61% to -$79.1 million in 2025.
  • Business Quant data shows Net Income for AUTL at -$79.1 million in Q3 2025, -$47.9 million in Q2 2025, and -$70.2 million in Q1 2025.